New NOVA nanobody target is live: IL-6 (Interleukin-6) IL-6 is one of the central signaling proteins behind inflammation and immune regulation. When dysregulated, it has been implicated in: - autoimmune disorders - chronic inflammation - neuroinflammation - blood-brain barrier disruption Making it a highly relevant target for inflammatory, neurological, and immune-related diseases. The IL-6 inhibitor market is already worth billions annually, with drugs targeting this pathway generating multi-billion dollar revenues across autoimmune and inflammatory indications, validating both the biological and commercial importance of the target. Miners across NOVA will now compete to design nanobodies targeting IL-6 in an open, adversarial discovery environment. Top submissions may also be selected for wet lab validation through our partnership with @Yalotein, helping close the loop between decentralized virtual screening and real-world biologics development. #Bittensor# #SN68# #DrugDiscovery# #Biotech# #Nanobodies# #DeSci#